Methods to Augment the Efficacy of Aspirin and Clopidogrel in Healthy Subjects (ASA Only) and Patients With Stable Coronary Artery Disease (Taking Clopidogrel Only) or (Taking Clopidogrel & ASA) With an Elevated Platelet Turnover (Reticulated Platelets). (Dual-Dosing)

NCT01011257 Phase 4 WITHDRAWN

The investigators will test the hypothesis that aspirin or clopidogrel taken twice daily will augment their antiplatelet efficacy in patients with an elevated platelet turnover (as measured by the proportion of reticulated (young) platelets) compared with once daily dosing.

Details

Lead sponsor	Neil Kleiman, MD
Phase	Phase 4
Status	WITHDRAWN
Start date	2009-09
Completion	2011-09

Conditions

• Coronary Artery Disease

Interventions

• Asprin
• Clopidogrel

Primary outcomes

• To look if dual dosing of aspirin and/or clopidogrel will augment antiplatelet efficacy in patients with elevated reticulated platelet turnover. — 1 year

Countries

United States